title: Updating the OMERACT filter: discrimination and feasibility.
abstract: The "Discrimination" part of the OMERACT Filter asks whether a measure discriminates between situations that are of interest. "Feasibility" in the OMERACT Filter encompasses the practical considerations of using an instrument, including its ease of use, time to complete, monetary costs, and interpretability of the question(s) included in the instrument. Both the Discrimination and Reliability parts of the filter have been helpful but were agreed on primarily by consensus of OMERACT participants rather than through explicit evidence-based guidelines. In Filter 2.0 we wanted to improve this definition and provide specific guidance and advice to participants.
authors.affiliation: From the Cardiovascular Research Methods Centre, Department of Epidemiology and Community Medicine, University of Ottawa; Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada; Departments of Epidemiology and Biostatistics, and Rheumatology, VU University Medical Center, Amsterdam, The Netherlands; University of Bristol Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, UK; Department of Occupational Sciences and Occupational Therapy, Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA; Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute, Maastricht University, Maastricht, The Netherlands; Australian Health Workforce Institute (AHWI), School of Population Health, University of Melbourne, Melbourne, Australia; Division of Musculoskeletal Disease, University of Leeds, and UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK; Versailles-Saint Quentin En Yvelines University, Department of Rheumatology, Ambroise Paré Hospital, APHP, Boulogne-Billancourt; Paris-Descartes University, Medicine Faculty, APHP, Cochin Hospital, Rheumatology B, Paris, France; Section of Rheumatology, Cardiff University School of Medicine, Cardiff, UK; Department of Rheumatology, Geffen School of Medicine at the University of California in Los Angeles; Los Angeles, California, USA; Université Pierre et Marie Curie (UPMC) - Paris 6, GRC-UMPC 08 (EEMOIS); AP-HP Pitié Salpêtrière Hospital, Department of Rheumatology, Paris; Université de Lorraine, Université Paris Descartes, Nancy, France; University of Leeds, Section of Musculoskeletal Disease, LIMM Chapel Allerton Hospital, Leeds West Yorkshire; University of the West of England, Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, UK; Department of Rh
authors.forename: George
authors.initials: G
authors.lastname: Wells
authors.forename: Dorcas E
authors.initials: DE
authors.lastname: Beaton
authors.forename: Peter
authors.initials: P
authors.lastname: Tugwell
authors.forename: Maarten
authors.initials: M
authors.lastname: Boers
authors.forename: John R
authors.initials: JR
authors.lastname: Kirwan
authors.forename: Clifton O
authors.initials: CO
authors.lastname: Bingham
authors.forename: Annelies
authors.initials: A
authors.lastname: Boonen
authors.forename: Peter
authors.initials: P
authors.lastname: Brooks
authors.forename: Philip G
authors.initials: PG
authors.lastname: Conaghan
authors.forename: Maria-Antonietta
authors.initials: MA
authors.lastname: D'Agostino
authors.forename: Maxime
authors.initials: M
authors.lastname: Dougados
authors.forename: Daniel E
authors.initials: DE
authors.lastname: Furst
authors.forename: Laure
authors.initials: L
authors.lastname: Gossec
authors.forename: Francis
authors.initials: F
authors.lastname: Guillemin
authors.forename: Philip
authors.initials: P
authors.lastname: Helliwell
authors.forename: Sarah
authors.initials: S
authors.lastname: Hewlett
authors.forename: Tore K
authors.initials: TK
authors.lastname: Kvien
authors.forename: Robert B
authors.initials: RB
authors.lastname: Landewé
authors.forename: Lyn
authors.initials: L
authors.lastname: March
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Mease
authors.forename: Mikkel
authors.initials: M
authors.lastname: Ostergaard
authors.forename: Lee
authors.initials: L
authors.lastname: Simon
authors.forename: Jasvinder A
authors.initials: JA
authors.lastname: Singh
authors.forename: Vibeke
authors.initials: V
authors.lastname: Strand
authors.forename: Désirée M
authors.initials: DM
authors.lastname: van der Heijde
mesh_terms: D004192:Discrimination, Psychological; D019317:Evidence-Based Medicine / Q000592:standards; D005240:Feasibility Studies; D006801:Humans; D010043:Outcome and Process Assessment, Health Care / Q000592:standards* / Q000639:trends*; D012216:Rheumatic Diseases / Q000145:classification* / Q000628:therapy*; D012219:Rheumatology / Q000592:standards*
keywords: DISCRIMINATION; FEASIBILITY; OUTCOME AND PROCESS ASSESSMENT; OUTCOME MEASURES IN RHEUMATOLOGY